Novo Nordisk Gains European Approval for Semaglutide 7.2 mg, Submits Application to FDA
On February 17, 2026, the European Commission approved a semaglutide injection dose of 7.2 mg for adults living with obesity after a clinical trial displayed substantial body weight reduction on average. Additionally, parent company Novo Nordisk has …